Journal ArticleDOI
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study.
Reads0
Chats0
TLDR
Addition of trastuzumab (T) to chemotherapy has transformed outcomes in pts with HER2-positive breast cancer and in pts who had received anthracyclines (A), T has been associated with...Abstract:
533^ Background: Addition of trastuzumab (T) to chemotherapy has transformed outcomes in pts with HER2-positive breast cancer. In pts who had received anthracyclines (A), T has been associated with...read more
Citations
More filters
Journal ArticleDOI
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar,Benjamin O. Anderson,Jame Abraham,Rebecca Aft,Doreen M. Agnese,Kimberly H. Allison,Sarah L. Blair,Harold J. Burstein,Chau T. Dang,Anthony D. Elias,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Jairam Krishnamurthy,Janice A. Lyons,P. Kelly Marcom,Jennifer M. Matro,Ingrid A. Mayer,Meena S. Moran,Joanne E. Mortimer,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Hope S. Rugo,Amy M. Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,Erica Stringer-Reasor,Melinda L. Telli,John H. Ward,Jessica Young,Jennifer L. Burns,Rashmi Kumar +34 more
TL;DR: The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Journal ArticleDOI
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Nadia Harbeck,Matthias W. Beckmann,Achim Rody,Andreas Schneeweiss,Volkmar Müller,Tanja Fehm,Norbert Marschner,Oleg Gluz,Iris Schrader,Georg Heinrich,Michael Untch,Christian Jackisch +11 more
TL;DR: Results of the pivotal phase III study CLEOPATRA in patients with HER2-positive metastatic breast cancer demonstrated that the addition of pertuzumab to first-line combination therapy with docetaxel and trastuzumAB significantly prolonged progression-free and overall survival without increasing cardiac toxicity.
Journal ArticleDOI
Cardiotoxicity of novel HER2-targeted therapies
TL;DR: Cardiac dysfunction rate of the novel HER2-targeted therapies is significantly lower than the trastuzumab and combination of these agents with trastzumab did not significantly increase the cardiac adverse events.
Journal ArticleDOI
Pertuzumab in HER2-positive breast cancer.
TL;DR: Pertuzumab is the first HER dimerization inhibitor with a mechanism of action complementary to trastuzumabs, and studies with anti-HER2 combination treatments indicate that the use of more than one HER2-targeted therapy was superior to one of these agents alone.
Journal ArticleDOI
Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer
TL;DR: Advances in the treatment of HER2-positive MBC are discussed, focusing on novel Her2-targeted therapies and HER2 -targeted agents recently approved by the United States Food and Drug Administration (FDA).
Related Papers (5)
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more